Toggle navigation

Biovail

This content is from:Premium

For ValueAct, There is Life After Valeant

The activist hedge fund’s 2017 performance was buoyed by a large position in Twenty-First Century Fox.
ByStephen Taub
January 31, 2018
亚博篮球怎么下串

Will History Repeat Itself In Biovail Suit?

Canadian pharmaceutical Biovail has lashed out at a number of hedge funds over what it claims is a conspiracy with research firms to drive down its stock prices, but if history repeats itself, three of the 22 defendants could eventually get off the hook.

March 07, 2006
亚博篮球怎么下串

Biovail Shareholders Slap SAC, Others With $4B Suit

About a month after Biovail Corp. filed a $6 billion action against 22 defendants, including hedge fund SAC Capital Management, its founder, Steven Cohen, and the research firm now known as Gradient Analytics, shareholders have followed suit with their own class action.

March 26, 2006
This content is from:365亚博

The Morning Brief: ValueAct Buys More Valeant Stock

The hedge fund firm is raising its stake as Pershing Square bails out.
ByStephen Taub
March 17, 2017
亚博篮球怎么下串

Giving HF A Taste Of Its Own Medicine

Biovail Corp. apparently had it up to here with hedge funds allegedly attacking the company in an effort to drive down its share price, and the Canadian pharmaceutical is about to give SAC Management a taste of its own medicine.

2006年2月23日
This content is from:Premium

Jeffrey Ubben’s ValueAct Capital to Return Some Capital to Investors

The news follows Ubben’s revelation earlier this year that his firm is putting more money into cash as it sees fewer investment opportunities.
ByStephen Taub
April 10, 2017
See More Articles